Replies to post #43061 on Innovation Pharmaceuticals Inc (IPIX)

[lucky9]

Wow imagine that, a voice of reason on the ctix board? How dare you?

[petemantx]

You may be right, but I am sure Dr M reviewed the B data carefully and made the determination as to it's potential and worth. If he was happy with it and they are so pumped that they referred to the acq. as equivalent to getting a "Willy Wonka Golden Ticket" I will go with their conclusion until shown otherwise.

I have heard the previous owner was a very smart man but was hated by big pharma for being a total jackass with whom to work. Could have deterred them from doing business with him. No backup, just a theory.

[MrCleanAlpha]

Where are you getting your information? In the press release I read Polymedix provided the following regarding the phase 2 study:

"In the study, brilacidin was safely administered and adverse events appeared to be exposure-related. Aside from mild, transient numbness and tingling, for which no patient discontinued treatment, the overall adverse event rates were under 10% in each dose group. Rare cases of transient systolic blood pressure elevations occurred in 6 of the 160 (3.8%) patients treated with brilacidin. Of the six patients, three were in the high dose group. The one patient in the low dose group that experienced high blood pressure was reported as having pre-existing hypertension.

PolyMedix scientists believe that the attributes of brilacidin, including rapid bactericidal action, efficacy driven by exposure and not time, long half-life, and a long post-antibiotic effect, support exploring shorter courses of treatment in future clinical studies."

The full PR can be found below.

http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=327979§ionID=&isEPVantage=no

[Chazz123]

http://www.sec.gov/Archives/edgar/data/1341843/000114420413013653/v337514_fwp.htm

No patient discontinued because of numbness and tingling

Most cases were mild; all were transient; no intervention necessary

[I Need Help]

I disagree with most of your points. Nothing wrong in disagreement. I learn a lot from opposing views. Often, it makes me dig harder to see if I am missing something.

Your "truth" makes no sense": You state, "Some think that many of the larger pharm and biotech's missed out but the truth is that it could be that decided to pass on what Polymedix had to offer." There can be no "could be" in truth. Either something is true or it is not. Sounds as if you are trying to push an idea as truth, but in reality can not demonstrate it to be so.

You cite some facts that I can not verify, "...but 85 % of the patients had suffered with severe numbness and tingling, 5 dropped out and there was at least one severe untoward reaction.
" Please, cite your source(s). I am also interested in reading not just the "facts" but also the context the facts are presented in. Otherwise, I will continue to believe what I have seen publically disclosed. And, those facts do not match your facts.

You state, "The CEO,Mr. Nicholas Landekic was in the pharmaceutical field for over 25 years and had ties and connections to Bristol Myers Squibb as well as Johnson and Johnson.
Do you honestly believe that he would not have contacted these people and told them of this great opportunity?" If I were to answer the question honestly, from all that is public knowledge, I would have to say, "I really do not know?" It is just as likely that Dr. Landekic was in contact with "our guys" as "their guys". True, there is much that is unknown. And, one could fault CTIX for not clearing many points up. Uncertainty, leads to speculation.

You last point is, "Never buy things at a fire sale because they may turn out to be wasteful..." I had to chuckle a bit when I read this. I am not a big believer in absolutes, and "Never" is one that raises red flags for me. I for one, have profited from more than a few "fire sales". I could have agreed with "Most" but not "Never". It just isn't true.

[damnthetorpedoes]

There are many people on this board who believe that Leo hit a grand slam when they bought the entire drug portfolio from the now bankrupt company called Polymedix.
Some think that many of the larger pharm and biotech's missed out but the truth is that it could be that decided to pass on what Polymedix had to offer.
Brilacidin had already been in a phase 2 study and appeared to show good therapeutic efficacy at low doses but 85 % of the patients had suffered with severe numbness and tingling, 5 dropped out and there was at least one severe untoward reaction.
The CEO,Mr. Nicholas Landekic was in the pharmaceutical field for over 25 years and had ties and connections to Bristol Myers Squibb as well as Johnson and Johnson.
Do you honestly believe that he would not have contacted these people and told them of this great opportunity?
No, I believe Leo should have stayed the course and they should pushed to trial Prurisol because it holds such great potential from the preclinical data.

As a former PYMX investor, I can respond to that.

"Brilacidin had already been in a phase 2 study and appeared to show good therapeutic efficacy at low doses but 85 % of the patients had suffered with severe numbness and tingling, 5 dropped out and there was at least one severe untoward reaction."
- Wrong! Numbness and tingling were characterized as mild and went away upon discontinuance, mostly at the end of the 5-day dosing regimen. In addition, analysis of the treated patients, including serum levels of Brilacidin, indicated a much shorter course of treatment at low dose levels would likely provide a full cure, thus minimizing the side effects.

"The CEO,Mr. Nicholas Landekic was in the pharmaceutical field for over 25 years and had ties and connections to Bristol Myers Squibb as well as Johnson and Johnson.
Do you honestly believe that he would not have contacted these people and told them of this great opportunity?"
- Yes, I believe either he would not have or that they refused to bargain with someone with his huge ego. Many times, Nick claimed Polymedix would "become the next Amgen". In reality, he pissed off so many both potential pharmaceutical partners and potential large investors that he alone was the primary reason for the company's ultimate failure. By the time the incompetent Board of Directors finally ousted him, it was way too late.

From the Brilacidin Fact Sheet:
"The most common adverse event experienced by patients in the study was numbness and tingling, felt by 65%-87% of treated patients. The majority of the cases were rated as mild and no patient discontinued due to just numbness and tingling. Excluding the numbness and tingling, the treatment-related adverse events were 9.6%, 5.6%, and 7.4% for the low, medium and high dose of bri-
lacidin vs. 10.9% for daptomycin. Eight patients discontinued treatment due to treatment-related adverse events. Three patients
that received brilacidin experienced a treatment-related serious adverse event Two of these patients discontinued treatment due
to hypertension (one medium dose and one high dose)."